Biotech Values

[rfj1862]

However I was expecting the results for the 1b trial in X-ALD more towards the end of the year (e.g. 4th q) rather than the next few months. I am thinking this because the 1b trial was still enrolling as of the 1st q cc which was 4-26. CEO Brian Lian in his prepared remarks then said:

Here's my thinking:

The study has been designed since 2021 and all study sites are on board. This is a rare disease with no good treatment options so enrollment of the 28 patients is going to be near immediate--I am sure they had patients waiting for study initiation. I would expect it is already fully enrolled; if last patient in was June 1, primary completion of all patients is in July and results in September. The endpoints are very simple and quick to assess.

CT.gov says primary completion Sept 30 but from experience those are always *extremely* conservative, sometimes they are months or even years off.

Here's the study design:

https://clinicaltrials.gov/ct2/show/NCT04973657?cond=VK0214&draw=2&rank=1#contacts